OptimizeRx financials
$8.36+7.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $109.4M | $92.1M | $71.5M | $62.5M | $61.3M | $43.3M | $24.6M | $21.2M |
| Gross profit | $73.6M | $59.4M | $42.9M | $39.0M | $35.6M | $24.1M | $15.4M | $12.2M |
| Gross margin | 67.3% | 64.5% | 60.0% | 62.4% | 58.1% | 55.7% | 62.8% | 57.6% |
| Operating income | $11.7M | -$13.7M | -$24.3M | -$12.3M | $361.1K | -$2.1M | -$3.7M | $180.1K |
| Net income | $5.1M | -$20.1M | -$17.6M | -$11.4M | $378.1K | -$2.2M | -$3.1M | $226.3K |
| Net margin | 4.7% | −21.8% | −24.6% | −18.3% | 0.6% | −5.1% | −12.8% | 1.1% |
| Diluted EPS | $0.27 | $-1.10 | $-1.03 | $-0.64 | $0.02 | $-0.15 | $-0.23 | $0.02 |
| EBITDA | $16.4M | -$1.9M | -$15.1M | -$10.3M | $2.3M | -$164.2K | -$2.5M | $496.6K |
| Operating cash flow | $18.7M | $4.9M | -$7.2M | $10.7M | $726.0K | -$6.3M | -$1.7M | $792.6K |
| Free cash flow | $18.7M | $4.8M | -$7.3M | $10.6M | $261.6K | -$6.4M | -$1.7M | $758.2K |
| Diluted shares | 19.0M | 18.3M | 17.1M | 17.8M | 17.7M | 14.8M | 13.4M | 11.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $23.4M | $13.4M | $13.9M | $18.2M | $84.7M | $10.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $55.9M | $0.00 | — |
| Total debt | $25.7M | $32.8M | $36.2M | $0.00 | $0.00 | $0.00 |
| Total assets | $176.9M | $171.2M | $183.4M | $134.7M | $141.0M | $60.3M |
| Total liabilities | $48.6M | $54.2M | $56.8M | $8.5M | $9.6M | $10.4M |
| Shareholders' equity | $128.3M | $117.0M | $126.6M | $126.1M | $131.4M | $50.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology